Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.5696
- Book/Share 9.1268
- PB 5.1916
- Debt/Equity 2.7512
- CurrentRatio 1.2663
- ROIC 0.1414
- MktCap 96209545000.0
- FreeCF/Share 7.5085
- PFCF 6.2874
- PE 15.9487
- Debt/Assets 0.5268
- DivYield 0.0525
- ROE 0.3465
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
Read More
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
Published: November 05, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Negative
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent protection, leading to revenue declines despite a strong dividend yield. Recent acquisitions and new product launches have underperformed versus management's ambitious targets, raising concerns about BMY's growth prospects through 2030.
Read More
10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 38.01% by October 2026, with Lexinfintech Holdings leading potential returns.
Read More
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Read More
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.
Read More
Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
Read More
Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Rates Going Lower Next Week: Our Top 5% Dividend Picks Could Soar
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
October's 5 Dividend Growth Stocks With Yields Up To 8.33%
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Every month, we screen for high-yield dividend yields, but those that also deliver relatively consistent growth with regular dividend increases. The parameters of the screening also include dividend safety, which factors in payout ratios, debt and free cash flow as some key metrics. While these names screen highly, it is important to remember that it is only an initial dive; more due diligence is necessary before making any investment decision.
Read More
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
REDMOND, Wash. and PRINCETON, N.J.
Read More
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry's gain of 4.8%.
Read More
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from new drugs like Breyanzi offset legacy drug declines. Political risks are manageable for BMY as a US-based company, with potential policy changes likely to have limited impact on its bottom line.
Read More
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Billionaires Are Piling Into United Health Group and These 2 Stocks
Published: October 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
UnitedHealth Group (NYSE:UNH ), Bristol-Myers Squibb (NYSE:BMY) and Fiserv (NYSE:FI) have been getting plenty of attention from big name investors.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100